Amgen Boosts Bid for Onyx to $130 a Share

Aug. 7 (Bloomberg) -- Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to a person familiar with the matter. Cristina Alesci reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
GOP Lawmakers Open New Avenue of Attack on Iran Nuke Deal
46:41 - Republican lawmakers have opened a new avenue of attack on the Iran nuclear accord by criticizing what they call “secret side deals” governing the inspection process that will be withheld from Congress. Bloomberg's Olivia Sterns and Pimm Fox report on "Bloomberg Markets." (Source: Bloomberg)
  • Cigna's Cordani 'Confident' Anthem Deal Will Be Approved
  • U.S. Economy Expanded at Faster Pace in 2Q
  • Will Congress Pass a Long-Term Bill to Fix Roads?